¼¼°èÀÇ ½Å°æÇ÷°ü »öÀü ±â±â ½ÃÀå
Neurovascular Embolization Devices
»óǰÄÚµå : 1787231
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 284 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License)
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)


Çѱ۸ñÂ÷

¼¼°èÀÇ ½Å°æÇ÷°ü »öÀü ±â±â ½ÃÀåÀº 2030³â±îÁö 15¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 12¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ½Å°æÇ÷°ü »öÀü ±â±â ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 4.6%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 15¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ »öÀüÄÚÀÏÀº CAGR 3.6%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 5¾ï 7,960¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ç÷·ù Àüȯ ±â±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 3.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3¾ï 1,540¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½Å°æÇ÷°ü »öÀü ±â±â ½ÃÀåÀº 2024³â¿¡ 3¾ï 1,540¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀ» 7.1%·Î, 2030³â±îÁö 2¾ï 9,400¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.2%¿Í 4.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ½Å°æÇ÷°ü»öÀü¼ú ±â±â ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

³úÁ¹Áß ¹× µ¿¸Æ·ù Ä¡·á¿¡ ½Å°æÇ÷°ü»öÀü¼úÀÌ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

½Å°æÇ÷°ü»öÀü¼úÀº µÎ°³³» µ¿¸Æ·ù, µ¿Á¤¸Æ ±âÇü(AVM) ¹× ±âŸ ³úÇ÷°ü ÁúȯÀÇ °ü¸®¿¡ ÀÖÀ¸¸ç, Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. »öÀüÄÚÀÏ, ¾×ü»öÀüÁ¦, À¯·®ºÐ¹è±â, Ç÷°üÇ÷¯±× µîÀÇ Àúħ½ÀÀû ÀåÄ¡´Â µ¿¸Æ·ù ÆÄ¿­À» ¿¹¹æÇϰí, ºñÁ¤»óÀûÀÎ Ç÷°üÀÇ Ç÷·ù¸¦ °¨¼Ò½ÃÄÑ ³ú¼øÈ¯À» ¾ÈÁ¤È­½Ã۵µ·Ï ¼³°èµÇ¾î ÀÖ½À´Ï´Ù. ³úÁ¹Áß°ú ÃâÇ÷¼º ÁúȯÀÌ Àü ¼¼°è¿¡¼­ Àå¾Ö¿Í »ç¸ÁÀÇ ÁÖ¿ä ¿øÀÎÀÌ µÇ°í ÀÖ´Â °¡¿îµ¥, ½Å°æÇ÷°ü»öÀü¼úÀº °³µÎ¼úÀ̳ª Ŭ¸®Çμú°ú °°Àº ÀüÅëÀûÀÎ ¼ö¼úÀû °³ÀÔÀ» ´ëüÇÒ ¼ö ÀÖ´Â È¿°úÀûÀÎ ¹æ¹ýÀ¸·Î ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. Ç÷°ü³» Ä¡·áÀÇ ¹ßÀüÀº ȯÀÚÀÇ ¿¹Èĸ¦ Å©°Ô °³¼±Çϰí, ȸº¹¿¡ µå´Â ½Ã°£°ú Ä¡·á ÈÄ ÇÕº´ÁõÀ» °¨¼Ò½Ã۰í ÀÖ½À´Ï´Ù. ƯÈ÷ flow diverters´Â ÀÌÀü¿¡´Â ¼ö¼úÀÌ ºÒ°¡´ÉÇÏ´Ù°í ¿©°ÜÁ³´ø °æºÎÀÇ ³Ð°í º¹ÀâÇÑ µ¿¸Æ·ù¸¦ Ä¡·áÇϱâ À§ÇÑ È¹±âÀûÀÎ ±â¼ú·Î µîÀåÇß½À´Ï´Ù. ¶ÇÇÑ ¾×ü»öÀüÁ¦´Â Ç÷°üÀ» Á¤È®ÇÏ°Ô ¸·°í ÃâÇ÷ÀÇ Àç¹ß À§ÇèÀ» ÁÙÀÓÀ¸·Î½á AVM Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ½Å°æÇ÷°ü ÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó »öÀü¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ½Å°æ ÁßÀç Ä¡·á¿¡¼­ ´õ ¸¹Àº ±â¼ú Çõ½Å°ú äÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½Å°æÇ÷°ü»öÀü¼úÀÇ µµÀÔÀ» °¡·Î¸·´Â Àå¾Ö¿äÀÎÀº ¹«¾ùÀΰ¡?

½Å°æÇ÷°ü»öÀü¼úÀÇ È¿°ú´Â ÀÔÁõµÇ¾úÁö¸¸, ¸î °¡Áö ¹®Á¦Á¡ÀÌ ½Å°æÇ÷°ü»öÀü¼úÀÇ º¸±ÞÀ» °¡·Î¸·°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿ì·Á »çÇ× Áß Çϳª´Â Ç÷°ü³» »öÀü¼úÀÇ ºñ¿ëÀÌ ºñ½Î°í, ÀÇ·á ÀÚ±ÝÀÌ ÇÑÁ¤µÈ Áö¿ª¿¡¼­´Â ÀÌ¿ëÇÏ±â ¾î·Æ´Ù´Â Á¡ÀÔ´Ï´Ù. ¶ÇÇÑ »öÀü¼úÀº ±â¼úÀûÀ¸·Î º¹ÀâÇϹǷΠ°íµµ·Î ÈÆ·ÃµÈ ½Å°æÁßÀç Àü¹®Àǰ¡ ÇÊ¿äÇϸç, Áö¹æÀ̳ª ¹Ì°³¹ßµÈ ÀÇ·á ½Ã½ºÅÛ¿¡¼­´Â ÀÌ¿ëÀÌ Á¦ÇѵǾî ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ Å« ¹®Á¦´Â Ç÷°ü õ°ø, ÇãÇ÷, »öÀü ¹°ÁúÀÇ À̵¿À» Æ÷ÇÔÇÑ ½Ã¼ú ÇÕº´ÁõÀÇ À§ÇèÀ̸ç, ÀÌ´Â ³úÁ¹ÁßÀ̳ª ½Å°æ Àå¾Ö¸¦ À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚÀÇ ÇØºÎÇÐÀû ±¸Á¶¿Í Ç÷°ü »óŰ¡ ´Ù¾çÇϹǷΠ°³Àκ° ¸ÂÃã Ä¡·á °èȹÀÌ ÇÊ¿äÇϸç, ÷´Ü ¿µ»ó Áø´Ü°ú ±¤¹üÀ§ÇÑ ½Ã¼ú Àü Æò°¡°¡ ÇÊ¿äÇÕ´Ï´Ù. »õ·Î¿î »öÀü¼ú ±â¼ú¿¡ ´ëÇÑ ±ÔÁ¦ À庮°ú ±ä ½ÂÀÎ ÁÖ±â·Î ÀÎÇØ ½ÃÀå È®´ë°¡ ´õµð°Ô ÁøÇàµÇ¾î Â÷¼¼´ë ½Å°æÇ÷°ü Ä¡·áÁ¦¿¡ ´ëÇÑ Á¢±ÙÀÌ ´Ê¾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àúħ½ÀÀû ½Å°æÇ÷°üÁßÀç¼ú¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ÀνÄÀÌ ¿©ÀüÈ÷ ³·¾Æ Áø´ÜÀÌ ´Ê¾îÁö°í »öÀü¼úÀÌ Á¦´ë·Î Ȱ¿ëµÇÁö ¸øÇϰí ÀÖ´Â ½ÇÁ¤ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇϱâ À§Çؼ­´Â ÀÇ»ç ±³À°¿¡ ´ëÇÑ ÅõÀÚ È®´ë, ÀåºñÀÇ ¾ÈÀü¼º°ú Á¤È®¼º Çâ»ó, »öÀü¼úÀÇ º¸±ÞÀ» À§ÇÑ ³ë·Â °­È­°¡ ÇÊ¿äÇϸç, À̸¦ À§Çؼ­´Â Àú·ÅÇÑ °¡°ÝÀÇ Á¦Ç° Ãâ½Ã°¡ ÇÊ¿äÇÕ´Ï´Ù.

±â¼ú Çõ½ÅÀº ½Å°æÇ÷°ü»öÀü¼úÀÇ È¿°ú¸¦ ¾î¶»°Ô Çâ»ó½Ãų ¼ö Àִ°¡?

½Å°æÇ÷°ü»öÀü¼ú ºÐ¾ß¿¡¼­´Â ½Ã¼ú ¼º°ø·üÀ» ³ôÀÌ°í º¹ÀâÇÑ ³úÇ÷°ü Áúȯ¿¡ ´ëÇÑ Ä¡·á ¿É¼ÇÀ» ³ÐÈ÷´Â ºü¸¥ ±â¼ú ¹ßÀüÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ ±â¼ú Çõ½Å Áß Çϳª´Â »ýüȰ¼º »öÀü ÄÚÀÏ °³¹ßÀÔ´Ï´Ù. ÀÌ ÄÚÀÏÀº ³»ÇǼ¼Æ÷ÀÇ Áõ½ÄÀ» ÃËÁøÇÏ¿© µ¿¸Æ·ùÀÇ ¸·ÈûÀ» ºü¸£°Ô Çϰí Àå±âÀûÀÎ Ç÷°ü Ä¡À¯¸¦ ÃËÁøÇÕ´Ï´Ù. ¶ÇÇÑ À¯¿¬¼º°ú À¯·® Á¶Àý ±â´ÉÀ» Çâ»ó½ÃŲ 2¼¼´ë À¯·®ºÐ¹è±âÀÇ µµÀÔÀ¸·Î Å©°í °æºÎ°¡ ³ÐÀº µ¿¸Æ·ù¿¡ ´ëÇÑ Ä¡·áÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. AI ±â¹Ý ¿µ»ó Áø´Ü°ú ·Îº¿ º¸Á¶ Ç÷°ü³» ³»ºñ°ÔÀ̼ÇÀÇ ÅëÇÕÀº Á¤È®ÇÑ »öÀü¼úÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ÇÕº´Áõ À§ÇèÀ» ÃÖ¼ÒÈ­Çϰí ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. Á¡µµ Á¶ÀýÀÌ °­È­µÈ ¾×ü»öÀüÁ¦ ¶ÇÇÑ Ç¥Àû Ç÷°ü ±¸Á¶¿¡ ´ëÇÑ Ä§Åõ¼º°ú Á¢Âø·ÂÀ» Çâ»ó½ÃÄÑ AVM Ä¡·á¸¦ ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ »öÀü¼ú ÈÄ ½Å°æ º¸È£ ¾à¸®ÇÐÀû ÁßÀç¿Í °°Àº º´¿ë ¿ä¹ýÀÇ ÃâÇöÀ¸·Î ½Å°æÇ÷°ü Ä¡·á Àü·«ÀÌ ´õ¿í ÃÖÀûÈ­µÇ°í ÀÖ½À´Ï´Ù. Àåºñ Á¦Á¶¾÷üµéÀÌ Áö¼ÓÀûÀ¸·Î »öÀü¼ú ±â¼úÀ» °³¼±ÇÔ¿¡ µû¶ó ½Å°æÁßÀç¼ú Ä¡·á´Â ´õ¿í ¾ÈÀüÇϰí È¿À²ÀûÀ̸ç, ´õ ¸¹Àº ȯÀÚµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

½Å°æÇ÷°ü»öÀü¼ú ±â±â ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

½Å°æÇ÷°ü»öÀü¼ú ½ÃÀåÀÇ ¼ºÀåÀº ³úÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, ÃÖ¼Òħ½ÀÀû ½Ã¼úÀÇ Ã¤Åà Áõ°¡, Ç÷°ü³» Ä¡·á ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀü µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. µÎ°³³» µ¿¸Æ·ù ¹× AVM ¹ß»ý·ü Áõ°¡´Â Àα¸ °í·ÉÈ­, °íÇ÷¾Ð, Èí¿¬°ú °°Àº »ýȰ½À°ü °ü·Ã À§Çè¿äÀο¡ ÈûÀÔ¾î È¿°úÀûÀÎ ½Å°æÇ÷°ü ÁßÀç¼ú¿¡ ´ëÇÑ °­·ÂÇÑ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. »öÀü¼úÀº °³µÎ¼ú¿¡ ºñÇØ ÀÌȯÀ²ÀÌ ³·°í ÀÔ¿ø ±â°£ÀÌ Âª¾Æ Àúħ½ÀÀû ±â¼ú·ÎÀÇ ÀüȯÀÌ ½ÃÀå È®´ë¸¦ ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. »ýüÈí¼ö¼º »öÀüÁ¦ ¹× ¹æ»ç¼± ºÒÅõ°ú¼º »öÀüÁ¦¸¦ Æ÷ÇÔÇÑ »öÀü Àç·áÀÇ ±â¼úÀû ¹ßÀüÀ¸·Î ½Ã¼úÀÇ Á¤È®¼º°ú ¾ÈÀü¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ 3D ȸÀüÇ÷°üÁ¶¿µ¼ú, °ü·ù MRI¿Í °°Àº ÷´Ü ½Å°æ¿µ»ó±â¼úÀÇ ¹ß´Þ·Î Áø´Ü°ú Ä¡·á°èȹÀÌ °³¼±µÇ°í, µµÀÔ·üÀÌ ³ô¾ÆÁö´Â °Íµµ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ³úÁ¹Áß Ä¡·á ÀÎÇÁ¶ó ±¸ÃàÀ» À§ÇÑ Á¤ºÎÀÇ ÀçÁ¤Áö¿ø Á¤Ã¥ È®´ë¿Í Á¤ºÎÀÇ ±¸»óµµ ½ÃÀå ¼ºÀå¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿Í ¿¬±¸±â°üÀÌ ½Å°æÇ÷°ü Çõ½Å¿¡ ´ëÇÑ ÅõÀÚ¸¦ Áö¼ÓÇÔ¿¡ µû¶ó º¹ÀâÇÑ ³úÇ÷°ü ÁúȯÀ» ¾Î°í Àִ ȯÀڵ鿡°Ô »ý¸íÀ» ±¸ÇÏ´Â ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â ½Å°æÇ÷°ü»öÀü¼ú ½ÃÀåÀº Å©°Ô È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(»öÀüÄÚÀÏ, Ç÷·ù Àüȯ ±â±â, ¾×ü»öÀüÁ¦, µ¿¸Æ·ù Ŭ¸³), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, Àü¹® Ŭ¸®´Ð ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Neurovascular Embolization Devices Market to Reach US$1.5 Billion by 2030

The global market for Neurovascular Embolization Devices estimated at US$1.2 Billion in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Embolic Coils, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$579.6 Million by the end of the analysis period. Growth in the Flow Diversion Devices segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$315.4 Million While China is Forecast to Grow at 7.1% CAGR

The Neurovascular Embolization Devices market in the U.S. is estimated at US$315.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$294.0 Million by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Neurovascular Embolization Devices Market - Key Trends & Drivers Summarized

Why Are Neurovascular Embolization Devices Essential in Stroke and Aneurysm Treatment?

Neurovascular embolization devices have become critical in the management of intracranial aneurysms, arteriovenous malformations (AVMs), and other cerebrovascular abnormalities. These minimally invasive devices, including embolic coils, liquid embolic agents, flow diverters, and vascular plugs, are designed to prevent aneurysm rupture, reduce blood flow to abnormal vessels, and stabilize cerebral circulation. With stroke and hemorrhagic conditions being leading causes of disability and mortality worldwide, neurovascular embolization procedures are gaining traction as an effective alternative to traditional surgical interventions such as craniotomy and clipping. The advancement of endovascular techniques has significantly improved patient outcomes, reducing recovery times and post-procedural complications. In particular, flow diverters have emerged as a game-changing technology for treating wide-necked and complex aneurysms that were previously considered inoperable. Additionally, liquid embolic agents are revolutionizing AVM treatment by allowing precise vessel occlusion, reducing the risk of recurrent hemorrhage. As the global burden of neurovascular diseases rises, the demand for embolization devices is increasing, driving further innovation and adoption in neurointerventional procedures.

What Challenges Are Hindering the Adoption of Neurovascular Embolization Devices?

Despite their proven efficacy, several challenges hinder the widespread adoption of neurovascular embolization devices. One of the primary concerns is the high cost of endovascular embolization procedures, making them less accessible in regions with limited healthcare funding. Additionally, the technical complexity of embolization procedures requires highly trained neurointerventionalists, limiting availability in rural and underdeveloped healthcare systems. Another significant challenge is the risk of procedural complications, including vessel perforation, ischemia, and migration of embolic materials, which can lead to stroke or neurological deficits. The variability in patient anatomy and vascular conditions also necessitates personalized treatment planning, requiring advanced imaging and extensive pre-procedural evaluation. Regulatory hurdles and long approval cycles for new embolization technologies further slow down market expansion, delaying access to next-generation neurovascular treatments. Moreover, patient awareness about minimally invasive neurovascular interventions remains low, leading to delayed diagnosis and underutilization of embolization therapies. Addressing these challenges will require greater investment in physician training, improvements in device safety and precision, and increased efforts to make embolization procedures more widely available and affordable.

How Are Innovations Enhancing the Effectiveness of Neurovascular Embolization Devices?

The field of neurovascular embolization is witnessing rapid technological advancements that are improving procedural success rates and expanding treatment options for complex cerebrovascular conditions. One of the most significant innovations is the development of bioactive embolic coils, which promote faster aneurysm occlusion and long-term vessel healing by encouraging endothelial cell growth. Additionally, the introduction of second-generation flow diverters with improved flexibility and flow modulation capabilities is enhancing treatment safety and effectiveness for large and wide-necked aneurysms. The integration of AI-powered imaging and robotic-assisted endovascular navigation is enabling precise embolization procedures, minimizing the risk of complications and improving patient outcomes. Liquid embolic agents with enhanced viscosity control are also advancing AVM treatment by providing better penetration and adhesion to targeted vascular structures. Moreover, the emergence of combination therapies-such as embolization followed by neuroprotective pharmacological interventions-is further optimizing neurovascular treatment strategies. As device manufacturers continue to refine embolization technologies, neurointerventional procedures are becoming safer, more efficient, and accessible to a broader patient population.

What Is Driving the Growth of the Neurovascular Embolization Devices Market?

The growth in the neurovascular embolization devices market is driven by several factors, including the rising prevalence of cerebrovascular diseases, increasing adoption of minimally invasive procedures, and continuous advancements in endovascular technology. The growing incidence of intracranial aneurysms and AVMs, fueled by aging populations and lifestyle-related risk factors such as hypertension and smoking, is creating a strong demand for effective neurovascular interventions. The shift toward minimally invasive techniques is further accelerating market expansion, as embolization procedures offer lower morbidity and shorter hospital stays compared to open surgeries. Technological advancements in embolization materials, including bioresorbable and radiopaque embolic agents, are enhancing procedural precision and safety. Additionally, the increasing availability of advanced neuroimaging techniques, such as 3D rotational angiography and perfusion MRI, is improving diagnosis and treatment planning, driving higher adoption rates. Expanding reimbursement policies and government initiatives aimed at improving stroke care infrastructure are also playing a crucial role in market growth. As healthcare providers and research institutions continue to invest in neurovascular innovation, the neurovascular embolization devices market is poised for substantial expansion, offering life-saving solutions for patients with complex cerebrovascular conditions.

SCOPE OF STUDY:

The report analyzes the Neurovascular Embolization Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Embolic Coils, Flow Diversion Devices, Liquid Embolic Agents, Aneurysm Clips); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â